Rakuten Securities Inc. Invests $164,000 in Novo Nordisk A/S (NYSE:NVO)

Rakuten Securities Inc. bought a new stake in Novo Nordisk A/S (NYSE:NVO) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,581 shares of the company’s stock, valued at approximately $164,000.

Several other hedge funds and other institutional investors have also made changes to their positions in NVO. Pacific Center for Financial Services grew its stake in shares of Novo Nordisk A/S by 100.0% in the third quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Copeland Capital Management LLC lifted its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Copeland Capital Management LLC now owns 282 shares of the company’s stock valued at $26,000 after purchasing an additional 141 shares during the last quarter. Bell Investment Advisors Inc lifted its holdings in Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares during the last quarter. Citizens National Bank Trust Department lifted its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Citizens National Bank Trust Department now owns 300 shares of the company’s stock valued at $27,000 after purchasing an additional 150 shares during the last quarter. Finally, Tyler Stone Wealth Management lifted its holdings in Novo Nordisk A/S by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after purchasing an additional 146 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on NVO. Morgan Stanley began coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target for the company. UBS Group began coverage on Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating for the company. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, April 1st. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.60.

Novo Nordisk A/S Stock Up 0.9 %

NVO opened at $124.55 on Thursday. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The company has a market capitalization of $558.92 billion, a P/E ratio of 46.04, a P/E/G ratio of 2.06 and a beta of 0.41. The stock has a fifty day moving average of $126.28 and a 200-day moving average of $110.42.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. On average, equities analysts expect that Novo Nordisk A/S will post 3.33 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were paid a $0.664 dividend. This represents a yield of 0.9%. The ex-dividend date was Friday, March 22nd. This is an increase from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is 49.17%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.